These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 324695)

  • 1. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 2. [On the enteral absorption of valproic acid (author's transl)].
    Oelkers W; Stoffels G; Schäfer H; Reith H
    Arzneimittelforschung; 1977; 27(5):1088-90. PubMed ID: 328020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacological aspects of valproate sodium.
    Wulff K; Flachs H; Würtz-Jorgensen A; Gram L
    Epilepsia; 1977 Jun; 18(2):149-57. PubMed ID: 326543
    [No Abstract]   [Full Text] [Related]  

  • 4. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
    Hoffmann F; Jancik BC; von Unruh GE
    Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of valproic acid in patients with liver disease.
    Klotz U; Rapp T; Müller WA
    Eur J Clin Pharmacol; 1978 Mar; 13(1):55-60. PubMed ID: 346355
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of valproic acid in man.
    Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU
    Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
    Anderson P; Elwin CE
    Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of sodium valproate in epileptic patients.
    Perucca E; Gatti G; Frigo GM; Crema A; Calzetti S; Visintini D
    Br J Clin Pharmacol; 1978 Jun; 5(6):495-9. PubMed ID: 350251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
    Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
    Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of enteric-coated valproic acid.
    Albright PS; Bruni J; Suria D
    Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic study of sodium di-n-propylacetate (usual tablet and enteric coated tablet with delayed absorption) (author's transl)].
    van de Mortel I; franck G
    Acta Neurol Belg; 1976; 76(3):165-72. PubMed ID: 788439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of valpromide in dogs after various modes of administration.
    Bialer M; Rubinstein A
    Biopharm Drug Dispos; 1984; 5(2):177-83. PubMed ID: 6430363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of digoxin in man after oral administration of preparations with different dissolution rate.
    Nyberg L
    Acta Pharmacol Toxicol (Copenh); 1977; 40 Suppl 3():1-48. PubMed ID: 301340
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic studies with valproic acid in man.
    Klotz U
    Arzneimittelforschung; 1977; 27(5):1085-8. PubMed ID: 328019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid in epilepsy: clinical and pharmacological effects.
    Mattson RH; Cramer JA; Williamson PD; Novelly RA
    Ann Neurol; 1978 Jan; 3(1):20-5. PubMed ID: 350128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.